ATXN1 一抗-ATXN1 Primary antibody代理/參數/廠家-一抗-艾美捷科技有限公司

PRODUCT CENTER

一抗

產品中心

當前位置：首頁 > 產品中心 > 免疫學產品 > 一抗

購買方式: Promab中國區(qū)現(xiàn)貨中心已經建立，95%產品中國有現(xiàn)貨庫存。銀行轉賬、電匯、支票、現(xiàn)金，在線支付寶及網銀支付，或直接與我們電話聯(lián)系。本公司所有產品僅供科研使用，不用于臨床診斷。

背景資料: The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. The function of the ataxins is not known. This locus has been mapped to chromosome 6, and it has been determined that the diseased allele contains 41-81 CAG repeats, compared to 6-39 in the normal allele. At least two transcript variants encoding the same protein have been found for this gene.Tissue specificity: Widely expressed throughout the body.

其他: ProMab 生物技術公司通過整合生物信息學、分子生物學、蛋白質表達、純化技術、基因克隆、微生物學和免疫學，利用新型高通量技術開發(fā)重組蛋白、抗體和工程細胞系并將其商業(yè)化。專注于免疫治療領域，特別是 CAR-T/NK 細胞技術。ProMab 還開發(fā)了一種新型的 mRNA 脂質納米顆粒（mRNA-LNP）平臺，用于即用型試劑和定制研究服務，以推進現(xiàn)有產品并擴展到更多的研究領域。